CDTX News and Press, Cidara Therapeutics Inc. From 04/14/21

Johnson & Johnson (NYSE: JNJ) hasn't been a major player in the vaccine market in the past, but that's changing. The healthcare giant is already marketing its COVID-19 vaccine. It's now seeking to develop a flu vaccine through a recent deal with small biotech Cidara Therapeuti...

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph....

Cidara Therapeutics (CDTX) soars 15% premarket after entering into an exclusive worldwide license and collaboration agreement with Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates (AVCs) for ...

Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...

Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding Cidara to advance CD388 through Phase 2 development funded by Janssen Conf...

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compens...

Today, we revisit Cidara Therapeutics for the first time in 10 months as analysts have grown more positive on it lately. This antifungal concern's primary drug candidate also has major peak sales potential according to management's projections. We circle back and update our invest...

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph....

Cidara Therapeutics (CDTX): Q4 GAAP EPS of -$0.49 misses by $0.25.Revenue of $3.73M (+104.9% Y/Y) misses by $6.48M.“We are pleased with our progress across our rezafungin Phase 3 trials and Cloudbreak platforms despite the pandemic-related challenges imposed during the course of 2020. ...

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the thre...